Barbé F, Mayoralas L R, Duran J, Masa J F, Maimó A, Montserrat J M, Monasterio C, Bosch M, Ladaria A, Rubio M, Rubio R, Medinas M, Hernandez L, Vidal S, Douglas N J, Agustí A G
Servei de Pneumologia, Hospital Universitari Son Dureta, Andrea Doria, 55, 07014 Palma de Mallorca, Spain.
Ann Intern Med. 2001 Jun 5;134(11):1015-23. doi: 10.7326/0003-4819-134-11-200106050-00007.
The sleep apnea-hypopnea syndrome is defined by a pathologic number of respiratory events during sleep (the apnea-hypopnea index, defined as the number of apnea and hypopnea episodes per hour) and daytime symptoms (mostly, excessive sleepiness). In patients with the sleep apnea syndrome, treatment with continuous positive airway pressure (CPAP) normalizes both the apnea-hypopnea index and diurnal symptoms. However, the effect of CPAP in persons with a pathologic apnea-hypopnea index without daytime sleepiness is unclear.
To investigate the short-term effects of CPAP on quality of life, objective sleepiness, cognitive function, and arterial blood pressure in nonsleepy patients with a pathologic apnea-hypopnea index.
Multicenter randomized, placebo-controlled, parallel-group study.
Six teaching hospitals in Spain.
55 patients with an apnea-hypopnea index of 30 or greater who did not have daytime sleepiness (Epworth Sleepiness Scale score </= 10).
Patients were randomly assigned to receive optimal (n = 29) or sham (n = 25) CPAP and were observed for 6 weeks.
Quality of life, objective sleepiness (Multiple Sleep Latency Test score), cognitive function, and arterial blood pressure.
The intervention and control groups were similar in terms of mean (+/-SE) age (54 +/- 2 vs. 52 +/- 2 years), apnea-hypopnea index (54 +/- 3 vs. 57 +/- 4), Epworth Sleepiness Scale score (7.0 +/- 0.4 vs. 7.0 +/- 0.4) and adherence to CPAP treatment (5.0 +/- 0.4 vs. 4.0 +/- 0.5 hours/d). Other variables, such as quality of life, cognitive function, and arterial blood pressure, were also similar in both groups before treatment. After 6 weeks of CPAP or sham CPAP, none of these variables changed significantly.
In patients with an apnea-hypopnea index of 30 or greater and no subjective daytime sleepiness, CPAP does not modify quality of life, objective sleepiness, vigilance, attention, memory, information processing, visuomotor coordination, or arterial blood pressure. Treatment with CPAP is therefore not indicated in nonsleepy patients with a pathologic apnea-hypopnea index.
睡眠呼吸暂停低通气综合征的定义是睡眠期间呼吸事件数量异常(呼吸暂停低通气指数,定义为每小时呼吸暂停和低通气发作次数)以及出现日间症状(主要是过度嗜睡)。在睡眠呼吸暂停综合征患者中,持续气道正压通气(CPAP)治疗可使呼吸暂停低通气指数和日间症状恢复正常。然而,CPAP对呼吸暂停低通气指数异常但无日间嗜睡的患者的影响尚不清楚。
探讨CPAP对呼吸暂停低通气指数异常的非嗜睡患者的生活质量、客观嗜睡程度、认知功能和动脉血压的短期影响。
多中心随机、安慰剂对照、平行组研究。
西班牙的六家教学医院。
55例呼吸暂停低通气指数≥30且无日间嗜睡(爱泼沃斯嗜睡量表评分≤10)的患者。
患者被随机分配接受最佳CPAP治疗(n = 29)或假CPAP治疗(n = 25),并观察6周。
生活质量、客观嗜睡程度(多次睡眠潜伏期试验评分)、认知功能和动脉血压。
干预组和对照组在平均(±标准误)年龄(54±2岁对52±2岁)、呼吸暂停低通气指数(54±3对57±4)、爱泼沃斯嗜睡量表评分(7.0±0.4对7.0±0.4)以及CPAP治疗依从性(5.0±0.4小时/天对4.0±0.5小时/天)方面相似。其他变量,如生活质量、认知功能和动脉血压,在治疗前两组也相似。CPAP或假CPAP治疗6周后,这些变量均无显著变化。
对于呼吸暂停低通气指数≥30且无主观日间嗜睡的患者,CPAP不会改善生活质量、客观嗜睡程度、警觉性、注意力、记忆力、信息处理能力、视觉运动协调性或动脉血压。因此,对于呼吸暂停低通气指数异常的非嗜睡患者,不建议使用CPAP治疗。